David Altshuler - Feb 1, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 1, 2022
Transactions value $
-$1,171,842
Form type
4
Date filed
2/3/2022, 03:06 PM
Previous filing
Nov 16, 2021
Next filing
Feb 14, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +8.17K +24.31% $0.00 41.8K Feb 1, 2022 Direct F1
transaction VRTX Common Stock Award $0 +11.6K +27.85% $0.00 53.4K Feb 1, 2022 Direct F2
transaction VRTX Common Stock Award $0 +12.3K +23.07% $0.00 65.7K Feb 1, 2022 Direct F3
transaction VRTX Common Stock Options Exercise $403K +4.66K +7.09% $86.52* 70.4K Feb 2, 2022 Direct
transaction VRTX Common Stock Sale -$124K -500 -0.71% $247.73 69.9K Feb 2, 2022 Direct F4, F5, F6
transaction VRTX Common Stock Sale -$31.6K -127 -0.18% $248.65 69.7K Feb 2, 2022 Direct F4, F6, F7
transaction VRTX Common Stock Sale -$188K -754 -1.08% $249.97 69K Feb 2, 2022 Direct F4, F6, F8
transaction VRTX Common Stock Sale -$246K -980 -1.42% $251.22 68K Feb 2, 2022 Direct F4, F6, F9
transaction VRTX Common Stock Sale -$227K -900 -1.32% $252.10 67.1K Feb 2, 2022 Direct F4, F6, F10
transaction VRTX Common Stock Sale -$278K -1.1K -1.64% $253.41 66K Feb 2, 2022 Direct F4, F6, F11
transaction VRTX Common Stock Sale -$76.3K -300 -0.45% $254.46 65.7K Feb 2, 2022 Direct F4, F6, F12

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise -$403K -4.66K -100% $86.52* 0 Feb 2, 2022 Common Stock 4.66K $86.52 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F3 Restricted stock unit award that vests in installments beginning on 02/24/2023.
F4 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F5 Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.35 to $248.34).
F6 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F7 Open market sales reported on this line occurred at a weighted average price of $248.65 (range $248.46 to $249.34).
F8 Open market sales reported on this line occurred at a weighted average price of $249.97 (range $249.61 to $250.33).
F9 Open market sales reported on this line occurred at a weighted average price of $251.22 (range $250.71 to $251.70).
F10 Open market sales reported on this line occurred at a weighted average price of $252.10 (range $251.75 to $252.72).
F11 Open market sales reported on this line occurred at a weighted average price of $253.41 (range $253.05 to $253.99).
F12 Open market sales reported on this line occurred at a weighted average price of $254.46 (range $254.34 to $254.58).
F13 Fully vested.

Remarks:

Exhibit 24 - Power of Attorney